Literature DB >> 19856215

Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.

Shintaro Fukushima1, Mizuhiko Terasaki, Kiyohiko Sakata, Naohisa Miyagi, Seiya Kato, Yasuo Sugita, Minoru Shigemori.   

Abstract

According to current World Health Organization (WHO) criteria, counting mitotic figures (MF), which is equal to the mitotic index (MI), on paraffin sections stained with hematoxylin and eosin (HE) is one of the recognized classification methods for meningiomas. However, it is not always easy to find the area of highest mitotic activity, and there are different perspectives among pathologists with regard to differentiating MF from non-MF, i.e., which are apoptotic figures and which are crushed or distorted cells. Moreover, there is an issue of overgrading in meningiomas with preoperative feeder embolization. Recently, anti-phosphohistone-H3 (PHH3) antibody has been reported as a mitosis-specific marker for meningioma grading. In this study, we attempted PHH3 immunostaining for our meningioma cases and verified not only the sensitivity of PHH3 immunostaining but also that of its usefulness in grading meningiomas. Forty-five initial histologically confirmed meningiomas (37 benign, 7 atypical, and 1 anaplastic) were reviewed according to current WHO criteria based on counting MF on HE-stained slides. PHH3-immunostained MF were counted in the same way, and the MIB-1 labeling index (LI) was calculated for each sample. PHH3-labeled MF were easily identified and permitted rapid recognition of the areas of highest mitotic activity. As a result, significant increase of PHH3 mitotic index (PHH3-MI) in comparison with HE mitotic index (HE-MI) and strong correlations with HE-MI to PHH3-MI as well as PHH3-MI to MIB-1 LI were demonstrated. Furthermore, no significant differences of PHH3-MI between cases with and without feeder embolization were demonstrated. As such, PHH3 may be a sensitive and useful marker for meningioma grading as based on the MF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856215     DOI: 10.1007/s10014-009-0249-9

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  17 in total

1.  Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Authors:  Eleonora Duregon; Adele Cassenti; Alessandra Pittaro; Laura Ventura; Rebecca Senetta; Roberta Rudà; Paola Cassoni
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

2.  Phosphohistone H3: implications for clinical practice and risk assessment in meningioma.

Authors:  Adriana Olar
Journal:  Neuro Oncol       Date:  2015-03-25       Impact factor: 12.300

3.  The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Authors:  Guro Aune; Astrid K Stunes; Solveig Tingulstad; Oyvind Salvesen; Unni Syversen; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2011-06-11

4.  Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.

Authors:  Arnaud Uguen; Gwenaël Conq; Laurent Doucet; Matthieu Talagas; Sebastian Costa; Marc De Braekeleer; Pascale Marcorelles
Journal:  Virchows Arch       Date:  2015-04-01       Impact factor: 4.064

5.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.

Authors:  Adriana Olar; Khalida M Wani; Erik P Sulman; Alireza Mansouri; Gelareh Zadeh; Charmaine D Wilson; Franco DeMonte; Gregory N Fuller; Kenneth D Aldape
Journal:  Brain Pathol       Date:  2014-10-29       Impact factor: 6.508

7.  MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.

Authors:  Theo L Winther; Sverre H Torp
Journal:  J Neurooncol       Date:  2016-11-21       Impact factor: 4.130

Review 8.  Pathological classification and molecular genetics of meningiomas.

Authors:  Christian Mawrin; Arie Perry
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

9.  Clinical and histopathological predictors of outcome in malignant meningioma.

Authors:  Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen
Journal:  Neurosurg Rev       Date:  2019-03-13       Impact factor: 3.042

10.  Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis.

Authors:  Min-Sung Kim; Se-Woong Chun; Yun-Sik Dho; Youngbeom Seo; Joo Ho Lee; Jae Kyung Won; Jin Wook Kim; Chul-Kee Park; Sung-Hye Park; Yong Hwy Kim
Journal:  Brain Tumor Pathol       Date:  2022-01-15       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.